Patients must communicate any increase in frequency or other atypical alterations in urination patterns to their healthcare provider for prompt and appropriate management
Telogen Effluviumin
According to KFF analysis of Centers for Medicare & Medicaid Services 2018-2022 Medicare Part D spending by drug increased from $57 Million to $5.7 Billion.[2] The June 13, 2024 article in Fierce Healthcare[3] on GLP-1 drugs noted that Blue Cross Blue Shield of Michigan will no longer cover these drugs starting in January 2025, and will be changing the prior authorization criteria starting in August 2024, for those members that are in large group fully insured commercial plans
In addition, the medication comes with common gastrointestinal side effects such as nausea, vomiting, diarrhea, and constipation, especially in the first month or during the dose escalation phase
Le GLP-1 agit en stimulant la production dinsuline et en rduisant la scrtion de glucagon, ce qui aide maintenir des niveaux stables de glucose dans le sang
Dextroamphetamine and Amphetamine